David Liew

3.7k total citations
74 papers, 839 citations indexed

About

David Liew is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, David Liew has authored 74 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Rheumatology, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Genetics. Recurrent topics in David Liew's work include Vasculitis and related conditions (14 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers). David Liew is often cited by papers focused on Vasculitis and related conditions (14 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers). David Liew collaborates with scholars based in Australia, United States and United Kingdom. David Liew's co-authors include Philip C. Robinson, Christopher McMaster, Russell Buchanan, Lianne S. Gensler, Sofía Ramiro, Albert G. Frauman, Duncan Richards, Marc Feldmann, Helen Tanner and Claire Owen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Kidney International.

In The Last Decade

David Liew

67 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Liew Australia	14	232	144	143	132	121	74	839
Sebastian E. Sattui United States	15	168 0.7×	101 0.7×	145 1.0×	80 0.6×	125 1.0×	53	772
Thomas El Jammal France	11	158 0.7×	400 2.8×	190 1.3×	131 1.0×	268 2.2×	27	1.1k
Kim Lauper Switzerland	13	494 2.1×	155 1.1×	181 1.3×	97 0.7×	36 0.3×	41	947
Montserrat Olona Spain	18	239 1.0×	122 0.8×	135 0.9×	102 0.8×	61 0.5×	50	1.1k
Vir Singh Negi India	21	458 2.0×	153 1.1×	232 1.6×	114 0.9×	169 1.4×	108	1.4k
Josef Zadražil Czechia	17	241 1.0×	33 0.2×	130 0.9×	102 0.8×	104 0.9×	88	983
Nadine Petitpain France	16	185 0.8×	50 0.3×	75 0.5×	97 0.7×	67 0.6×	74	1.1k
David M. Hughes United Kingdom	19	459 2.0×	167 1.2×	122 0.9×	133 1.0×	128 1.1×	87	1.2k
Malcolm L. Brigden Canada	18	160 0.7×	64 0.4×	105 0.7×	137 1.0×	190 1.6×	50	1.1k
Aldo Salvi Italy	17	174 0.8×	79 0.5×	232 1.6×	100 0.8×	94 0.8×	49	1.4k

Countries citing papers authored by David Liew

Since Specialization

Citations

This map shows the geographic impact of David Liew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Liew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Liew more than expected).

Fields of papers citing papers by David Liew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Liew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Liew. The network helps show where David Liew may publish in the future.

Co-authorship network of co-authors of David Liew

This figure shows the co-authorship network connecting the top 25 collaborators of David Liew. A scholar is included among the top collaborators of David Liew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Liew. David Liew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Laura S., Maureen Dubreuil, James S. Andrews, et al.. (2025). Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Lara D. Veeken. 64(6). 3434–3443. 3 indexed citations

Gianoudis, Jenny, et al.. (2025). Changes to physical function and body composition during the first 2 years of polymyalgia rheumatica. Lara D. Veeken. 64(11). 5834–5843.

Liew, David, et al.. (2025). Higher Rates of Depression in Polymyalgia Rheumatica Are Strongly Associated With Poor Physical Function. JCR Journal of Clinical Rheumatology. 31(4). 170–174.

Ghosh, Nilasha, Bridget Jivanelli, Namrata Singh, et al.. (2024). The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis. Rheumatic Disease Clinics of North America. 50(2). 325–335. 2 indexed citations

Liew, David, Sarah Mackie, Alice Tison, et al.. (2024). Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. Rheumatic Disease Clinics of North America. 50(2). 255–267. 4 indexed citations

Baraff, Aaron, Katherine D. Wysham, David Liew, et al.. (2024). Escalation to Biologics After Methotrexate Among US Veterans With Rheumatoid Arthritis Grouped by Rural Versus Urban Areas. Arthritis Care & Research. 77(1). 23–29.

Hill, Catherine, et al.. (2024). Navigating high‐cost medicines: summary of the Guiding Principles for the governance of high‐cost medicines in Australian hospitals. Internal Medicine Journal. 54(10). 1733–1738. 1 indexed citations

Sepriano, Alexandre, Elena Nikiphorou, René Østgård, et al.. (2024). A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a “Safety Checklist”. Drug Safety. 47(11). 1075–1093. 1 indexed citations

Owen, Claire, Aurora Poon, Bonnia Liu, et al.. (2023). Characterising polymyalgia rheumatica on whole-body 18F-FDG PET/CT: an atlas. Rheumatology Advances in Practice. 8(1). rkae003–rkae003. 9 indexed citations

10.

Kragstrup, Tue Wenzel, Christopher McMaster, Pankti Reid, et al.. (2023). Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Safety. 46(11). 1049–1071. 29 indexed citations

11.

Reid, Pankti, David Liew, Alexander C. Peterson, et al.. (2023). JAK inhibitors and black box warnings: what is the future for JAK inhibitors?. Expert Review of Clinical Immunology. 19(11). 1385–1397. 11 indexed citations

12.

Owen, Claire, Max Yates, David Liew, et al.. (2023). Imaging of giant cell arteritis – recent advances. Best Practice & Research Clinical Rheumatology. 37(1). 101827–101827. 3 indexed citations

13.

Robinson, Philip C., David Liew, Helen Tanner, et al.. (2022). COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences. 119(15). e2119893119–e2119893119. 92 indexed citations

14.

Kragstrup, Tue Wenzel, Bente Glintborg, Christopher McMaster, et al.. (2022). Waiting for JAK inhibitor safety data. RMD Open. 8(1). e002236–e002236. 64 indexed citations

15.

Robinson, Philip C., Robert Terkeltaub, Michael H. Pillinger, et al.. (2021). Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. The American Journal of Medicine. 135(1). 32–38. 68 indexed citations

16.

Rischin, Adam, David Liew, Rachel Black, et al.. (2021). Healthcare access and attitudes towards telehealth during the early phase of the COVID‐19 pandemic among an Australian cohort with inflammatory arthritis. Internal Medicine Journal. 51(5). 788–792. 4 indexed citations

17.

Robinson, Philip C., David Liew, Jean W. Liew, et al.. (2020). The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med. 1(1). 90–102. 88 indexed citations

18.

McMaster, Christopher, et al.. (2019). A Machine-Learning Algorithm to Optimise Automated Adverse Drug Reaction Detection from Clinical Coding. Drug Safety. 42(6). 721–725. 27 indexed citations

19.

Liew, David, et al.. (2017). Medicinal mishap: Fatal azathioprine toxicity. Australian Prescriber. 40(3). 109–109. 1 indexed citations

20.

Bohensky, Megan, et al.. (2015). 344O Cost-effectiveness of nivolumab in combination with ipilimumab in patients with unresectable advanced melanoma in Australia. Annals of Oncology. 26. ix103–ix103. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact